Clinical Trial Update: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) [Phase 2]

View source ↗

Summary

Phase 2 trial updates on Everolimus with or without estrogen deprivation therapy in unresectable fibrolamellar hepatocellular carcinoma; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Carcinoma
• Fibrolamellar Hepatocellular Carcinoma

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-12-29